-
BCYC Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Bicycle Therapeutics (BCYC)
Company Profile
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 880.07 mm | 880.07 mm | 880.07 mm | 880.07 mm | 880.07 mm | 880.07 mm |
Cash burn (monthly) | 3.78 mm | (no burn) | 22.55 mm | 17.49 mm | 3.13 mm | 13.73 mm |
Cash used (since last report) | 8.97 mm | n/a | 53.50 mm | 41.48 mm | 7.43 mm | 32.56 mm |
Cash remaining | 871.10 mm | n/a | 826.57 mm | 838.58 mm | 872.64 mm | 847.51 mm |
Runway (months of cash) | 230.4 | n/a | 36.6 | 47.9 | 278.6 | 61.7 |
13F holders | Current |
---|---|
Total holders | 103 |
Opened positions | 17 |
Closed positions | 24 |
Increased positions | 29 |
Reduced positions | 35 |
13F shares | Current |
---|---|
Total value | 542.87 bn |
Total shares | 49.93 mm |
Total puts | 17.40 k |
Total calls | 4.10 k |
Total put/call ratio | 4.2 |
Largest owners | Shares | Value |
---|---|---|
Baker Bros. Advisors | 10.89 mm | $152.39 bn |
Point72 Asset Management | 4.55 mm | $63.77 bn |
Forbion Growth Opportunities Fund II Cooperatief U.A. | 3.45 mm | $50.68 mm |
FCPM Iii Services B.V. | 3.45 mm | $48.33 bn |
Westfield Capital Management | 2.61 mm | $36.54 bn |
Armistice Capital | 2.20 mm | $30.74 bn |
Siren, L.L.C. | 1.84 mm | $25.75 bn |
T. Rowe Price | 1.59 mm | $22.19 mm |
SVLSF V | 1.56 mm | $54.41 mm |
GSK GSK | 1.53 mm | $39.40 mm |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Jan 25 | Nigel Crockett | Ordinary Shares | Sell | Dispose S | No | No | 14.75 | 936 | 13.81 k | 51,053 |
3 Jan 25 | Alistair Milnes | Ordinary Shares | Sell | Dispose S | No | No | 14.75 | 936 | 13.81 k | 99,788 |
2 Jan 25 | Baker Bros. Advisors | American Depositary Shares | Grant | Acquire A | Yes | No | 0 | 4,400 | 0.00 | 9,999,674 |
2 Jan 25 | Baker Bros. Advisors | American Depositary Shares | Grant | Acquire A | Yes | No | 0 | 4,400 | 0.00 | 918,483 |
2 Jan 25 | Baker Bros. Advisors | Share Option [object Object] | Grant | Acquire A | Yes | No | 14 | 8,801 | 123.21 k | 8,801 |
2 Jan 25 | Baker Bros. Advisors | Share Option [object Object] | Grant | Acquire A | Yes | No | 14 | 8,801 | 123.21 k | 8,801 |
2 Jan 25 | Legault Pierre | Ordinary Shares | Grant | Acquire A | No | No | 0 | 12,500 | 0.00 | 46,000 |
2 Jan 25 | Legault Pierre | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 14 | 25,000 | 350.00 k | 25,000 |
2 Jan 25 | Nigel Crockett | Ordinary Shares | Sell | Dispose S | No | No | 14.09 | 2,583 | 36.39 k | 51,989 |
2 Jan 25 | Nigel Crockett | Ordinary Shares | Grant | Acquire A | No | No | 0 | 8,750 | 0.00 | 54,572 |